Edgewise Therapeutics (EWTX) Accumulated Expenses (2020 - 2026)

Edgewise Therapeutics has disclosed Accumulated Expenses across 7 years of filings, most recently posting $5.7 million for Q1 2026.

• Accumulated Expenses for Q1 2026 came in at $5.7 million, up 42.88% year-over-year; the trailing twelve-month figure through Mar 2026 was $5.7 million (up 42.88% YoY), and the FY2025 annual result was $12.4 million, up 23.61% from the prior year.
• Accumulated Expenses came in at $5.7 million for Q1 2026 at Edgewise Therapeutics, down from $12.4 million in the prior quarter.
• In the past five years, Accumulated Expenses ranged from a high of $12.4 million in Q4 2025 to a low of $2.1 million in Q1 2023.
• The 5-year median for Accumulated Expenses is $5.6 million (2025), against an average of $5.6 million.
• Across the five-year window, Accumulated Expenses soared 210.27% in 2022 and slumped 37.49% in 2023, its largest moves.
• Edgewise Therapeutics' Accumulated Expenses stood at $4.0 million in 2022, then soared by 41.25% to $5.7 million in 2023, then soared by 76.58% to $10.1 million in 2024, then climbed by 23.61% to $12.4 million in 2025, then slumped by 54.32% to $5.7 million in 2026.
• The last three Accumulated Expenses figures came in at $5.7 million (Q1 2026), $12.4 million (Q4 2025), and $8.0 million (Q3 2025), per Business Quant data.